Targeting Doctors to Lower Drug Costs By Dan

New Post Public Reply Private Reply Replies (1) Message Board
incubus
Targeting Doctors to Lower Drug Costs

By Dan Gilmore

Mar. 9, 2016

Medication, like every other aspect of America’s health care industry, is a metastasizing mass of government rules, large companies and some feeble attempts at the free market. Recently, the Centers for Medicare and Medicaid Services introduced a rule1 that tries to reduce the number of times doctors prescribe medication with high cost. Currently, the cost of medication through Medicare Plan B runs the government about $19 billion a year. Currently, when doctors prescribe medication, they receive a payout of 6% of the cost of the drug. Drug costs $100? Doctor gets paid $6. Some point out that this “commission,” if you will, encourages doctors to scribble out prescriptions for more expensive drugs.

Dr. Allen Litcher, CEO of the American Society of Clinical Oncology told the WSJ that the government is laying the blame for high drug costs on the wrong people. “It is inappropriate for CMS to manipulate choice of treatment for cancer patients using heavy-handed reimbursement techniques,” he said. “Physicians did not create the problem of drug pricing and its solution should not be on their backs.”

The new rule is more complicated — not an encouraging first sign for reform — and it would first drop the premium to 2.5% of the price of the drug and go to a fee-based system. The goal is to remove the incentive from doctors to prescribe more expensive drugs for better cash and instead put the focus on what drugs work, preferably less expensive drugs.

But the larger problem remains: Just how did the nation’s medication get so expensive? Last year, WSJ examined the factors2, comparing the cost of name-brand drugs across several countries against the cost the U.S. government pays for them. Most of the time, American patients pay more than someone in, say, Norway or England. Some of the costs passed on to the consumer are because drug companies can advertise to consumers in the United States, unlike a more socialist nation where they are banned from doing so. In other instances, drug entrepreneurs like Martin Shkreli realize they can make a killing by jacking up prices. When he was called before Congress3 in February, he smirked, almost laughed at the lawmakers during the hearings and all the while remained silent before their questioning. Later Shkreli tweeted, “Hard to accept that these imbeciles represent the people in our government.”

But perhaps the biggest factor for the price disparity is that Norway, England and other “enlightened” socialist countries place price controls on drugs. This means that if drug companies want money to spend on research and development, they have to pull it from the pockets of consumers. It’s something America could do too, but at the cost of more regulation and less ability to develop life-saving drugs. Yet there the market forces remain. Patients can still insist on more inexpensive medication.

( What this article fails to include is that generics have different fillers, inactive ingredients that can have side effects and fail to provide the same potency. Many of these drugs are now produced overseas. Some generics have been found to have nonrelated active drugs in them. Our government doesn't do an effective job of screening them, tells us to take them. This deters new drug development due to underfunding especially for the smaller drug companies. A lot of articles on Google talking about it. Know this from personal experience. Even the pharmacy tries to force people to generics. My doctor told me to take brand only. And we have two Democrat 'candidates' attacking the industry causing it to plummet. The insurance companies now feel justified to force people to use them or pay much higher price for their medications.)

http://patriotpost.us/posts/41202

1.http://www.wsj.com/articles/u-s-officials-propose-test-program-aimed-at-lowering-medicare-drug-costs-1457470874
2.http://www.wsj.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481
3.http://www.usatoday.com/story/money/2016/02/04/martin-shkreli-congressional-testimony-turing-pharmaceuticals-valeant-fda-drug-prices/79808004/

www.newsmax.com/Health/Health-News/generic-drugs-danger-recall/2014/09/23/id/596332/

http://www.huffingtonpost.com/2015/02/22/gene...30194.html

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 7

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 5

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 5

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Merit Advisors Shines as Top Energy Workplace

Updated Category News Views 1

Well, here's something to chew on—Merit Advisors just grabbed the top spot on Hart Energy's first-ever Best Places to Work in Energy list. If you haven't heard of them, Merit's the heavyweight champ in specialty tax for the energy sector. This isn't just a shiny trophy on the shelf; it's a nod to the kind of culture that's making waves in an industry that's no stranger...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 3

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 12

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 4

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
World Fire Congress 2026 Champions Global Fire Safety

Updated Category News Views 1

Rethinking Fire Safety with a Global Mindset The 2026 World Fire Congress wrapped up in London, signaling a big shift in how we tackle fire safety. Over 60 nations were represented, and they all walked away singing the same tune: if we’re going to handle these ever-mounting fire risks, we have to lean on each other a lot more. Next stop on this crusade? The flashy city...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 5

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading

Top 5 Most Recently Viewed Articles

Cheers Act: Revamping America's Bars and Restaurants

Updated Category News Views 598

Understanding the CHEERS Act and Its Impact The CHEERS Act, or the Creating Hospitality Economic Enhancement for Restaurants and Servers Act, has gained traction in Washington, D.C., thanks to bipartisan support from key legislators. The initiative aims to provide essential tax relief to bars, restaurants, taprooms, and entertainment venues that incorporate draft beer...

Continue Reading
Harnessing AI for Enhanced Content Automation Solutions

Updated Category News Views 151

The Transformative Role of AI in Content Automation As we step into a new era characterized by rapid technological advancement, artificial intelligence (AI) is revolutionizing the realm of content automation. Businesses across various sectors are increasingly leveraging AI to streamline their content creation processes, resulting in a more efficient workflow and...

Continue Reading
Urgently Inc. Announces Impressive Q1 2025 Financial Overview

Updated Category News Views 235

Urgently Inc. Reports Financial Highlights for First Quarter 2025 Urgently Inc. (NASDAQ: ULY), a notable provider of digital roadside assistance technologies, has officially released its financial results for the first quarter. The results indicate a strong start to the fiscal year, highlighted by significant improvements across various financial metrics. Key Financial...

Continue Reading
Implantica's Breakthrough Study Results Propel RefluxStop™ Forward

Updated Category News Views 62

Results of Implantica's Innovative CE Mark Study Implantica AG (publ.) is a leading medtech company known for its innovative healthcare solutions. Their focus centers on the RefluxStop™ device, designed specifically to treat acid reflux, a condition that affects over one billion people worldwide. Recently, Implantica completed a comprehensive five-year CE mark study,...

Continue Reading
Pye-Barker Expands with the Acquisition of Systems Design Group

Updated Category News Views 116

Pye-Barker Fire & Safety Expands Its Reach Pye-Barker Fire & Safety has made a significant move to enhance its service capabilities by acquiring Systems Design Group (SDG). This acquisition marks an important milestone for Pye-Barker as they continue to grow as the premier provider of fire protection and life safety services across the nation. Enhancing Customer Service...

Continue Reading